mobile-logo
 

All News

03 Oct

Meet our new Chief Operating Officer, Dr Pete Sargent!

by Charmaine Fraser
in Blog
Comments

Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential!   Q: What attracted you to the role at Physiomics? A: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies...

Read More
03 Oct

Senior Management Announcement

by Jim Millen
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.   Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many...

Read More
20 Sep

Conference Attendance Announcement

by Charmaine Fraser
in Events
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on 11-15th October 2023.   Physiomics will be presenting a poster entitled “Preclinical pharmacokinetic (PK) and tumor growth inhibition (TGI) modeling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoral...

Read More
11 Sep

News update from Physiomics September 2023

by Charmaine Fraser
in Blog
Comments

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news   Exciting new contract with Numab! We are pleased to announce that we have been awarded a further contract by existing client, Numab Therapeutics. The project...

Read More
04 Sep

Senior Management Update

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring of a new member of its senior management team.  Effective today, Dr Peter Sargent will be joining the Company as Chief Operating Officer ("COO").   Prior to joining us, Dr Sargent held a senior management role at global consultancy...

Read More
31 Aug

Contract Award

by Jim Millen
in Other News
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded its first contract with a new UK-based biotech client.  The contract, which has a value of £125,000 and relates to a project in the immune-oncology field, is expected to be completed within this calendar year. Physiomics CEO, Dr Jim...

Read More
31 Aug

Merck contract award

by Jim Millen
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Merck KGaA that it expects to be completed over the next three months.  The project will involve pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage/ repair...

Read More
08 Aug

Contract award

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client, Numab Therapeutics (“Numab”).  The project involves PKPD modelling in support of one of Numab’s clinical programs and follows on from earlier work conducted by Physiomics on the same asset.  The project will...

Read More
04 Aug

Contract award

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics (“Bicycle”) that it expects to be completed over the next six months.  The project involves modelling and the use of bioinformatics data in support of target identification for undisclosed Bicycle...

Read More